A Phase I/IIa Double-Blind, Randomized, Placebo-controlled Dose-Finding Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults With and Without Latent Tuberculosis Infection
Phase of Trial: Phase I/II
Latest Information Update: 09 Aug 2018
Price : $35 *
At a glance
- Drugs H56IC (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Aeras
- 09 Aug 2018 Results published in the American Journal of Respiratory and Critical Care Medicine.
- 19 Feb 2018 According to an Aeras media release, data from this trial will be presented at the 5th Global Forum on TB Vaccines 2018.
- 04 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.